Could a common antiviral drug save lives in advanced HIV?
NCT ID NCT07379203
First seen Feb 01, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will receive either the drug or a placebo daily for 4 weeks, while continuing standard HIV care. Researchers will monitor side effects and check if the drug reduces hospitalizations or deaths.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV)INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.